医药行业：海外MNC动态跟踪系列（一）-诺和诺德：司美格鲁肽有望冲击药王，长效胰岛素表现亮眼

Investment Rating - The industry investment rating is "Outperform the Market" [32] Core Viewpoints - Novo Nordisk's revenue for 2024 reached 290.4 billion Danish Krone (approximately 42.15 billion USD), representing a year-on-year growth of 25.03% [4][12] - The key product, semaglutide, is expected to challenge the title of "King of Drugs," with total revenue from three semaglutide products in 2024 amounting to 201.85 billion Danish Krone (approximately 29.30 billion USD) [4][17] - Novo Nordisk holds a 55.1% market share in the global GLP-1 market and 44% in the global insulin market, with insulin product revenue growing by 17% to 55.37 billion Danish Krone (approximately 8.04 billion USD) [4][21] Summary by Sections 2024 Financial Overview and Key Events - Novo Nordisk's main business segments include diabetes, obesity, and rare diseases, with diabetes revenue at 206.62 billion Danish Krone (approximately 29.73 billion USD), obesity revenue at 65.15 billion Danish Krone (approximately 9.36 billion USD), and rare diseases revenue at 18.6 billion Danish Krone (approximately 2.66 billion USD) [12][18] Core Product Sales Analysis - Semaglutide sales in 2024 included 120.34 billion Danish Krone (approximately 17.47 billion USD) from Ozempic, 23.30 billion Danish Krone (approximately 3.38 billion USD) from Rybelsus, and 58.21 billion Danish Krone (approximately 8.48 billion USD) from Wegovy, with Wegovy showing an impressive growth of 86% [17][21] - The insulin segment saw a revenue increase of 17% to 55.37 billion Danish Krone (approximately 8.04 billion USD), driven by long-acting insulin sales, which grew by 30% [21][22] 2025 Pipeline Milestones - Key milestones for 2025 include expected completion of regulatory approvals for semaglutide in treating chronic kidney disease and clinical trial data readouts for CagriSema [24][26] - The obesity segment anticipates submissions for semaglutide in treating heart failure and obesity, with several clinical trials expected to conclude in the first half of 2025 [24][26] 2025 Financial Outlook - Novo Nordisk projects a sales growth of 16%-24% and an operating profit increase of 19%-27% for 2025, with capital expenditures estimated at 65 billion Danish Krone and free cash flow between 75-85 billion Danish Krone [28][29]